{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:38:08Z","timestamp":1762868288245,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.taap.2020.115239","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T11:40:59Z","timestamp":1600083659000},"page":"115239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy"],"prefix":"10.1016","volume":"406","author":[{"given":"Przemys\u0142aw J.","family":"Danek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"W\u00f3jcikowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u0142adys\u0142awa A.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2020.115239_bb0005","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/17425255.2014.908185","article-title":"Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism","volume":"10","author":"Citrome","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.taap.2020.115239_bb0010","doi-asserted-by":"crossref","DOI":"10.1007\/s43440-020-00102-5","article-title":"The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions","author":"Danek","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.taap.2020.115239_bb0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0278-5846(02)00317-2","article-title":"Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions","volume":"27","author":"Daniel","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.taap.2020.115239_bb0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/17425255.1.2.203","article-title":"The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms","volume":"1","author":"Daniel","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.taap.2020.115239_bb0025","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11920-012-0284-9","article-title":"Clinically significant psychotropic drug-drug interactions in the primary care setting","volume":"14","author":"English","year":"2012","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.taap.2020.115239_bb0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10565-011-9208-4","article-title":"Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins","volume":"28","author":"Gerets","year":"2012","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.taap.2020.115239_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.taap.2020.115239_bb0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40263-013-0114-6","article-title":"Clinically significant drug interactions with atypical antipsychotics","volume":"27","author":"Kennedy","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.taap.2020.115239_bb0045","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J."},{"key":"10.1016\/j.taap.2020.115239_bb0050","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1211\/jpp.58.7.0001","article-title":"Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents","volume":"58","author":"Murray","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.taap.2020.115239_bb0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1139\/jpn.0312","article-title":"Interactions between the cytochrome P450 system and the second-generation antipsychotics","volume":"28","author":"Prior","year":"2003","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.taap.2020.115239_bb0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/dmd.111.042028","article-title":"Interindividual variability in gene expression profiles in human hepatocytes and comparison with HepaRG cells","volume":"40","author":"Rogue","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2020.115239_bb0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bcp.2016.04.017","article-title":"The reverse role of the hypothalamic paraventricular (PVN) and arcuate (ARC) nuclei in the central serotonergic regulation of the liver cytochrome P450 isoform CYP2C11","volume":"112","author":"Rysz","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2020.115239_bb0070","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/15563650.2017.1388385","article-title":"Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers","volume":"56","author":"Stassinos","year":"2018","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.taap.2020.115239_bb0075","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0033-3182(10)70737-4","article-title":"The impact of serious mental illness on health and healthcare","volume":"51","author":"Viron","year":"2010","journal-title":"Psychosomatics"},{"key":"10.1016\/j.taap.2020.115239_bb0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjmed.2011.05.002","article-title":"Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population","volume":"125","author":"Viron","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.taap.2020.115239_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/WNF.0b013e3182aa38c4","article-title":"Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics","volume":"36","author":"Wang","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.taap.2020.115239_bb0090","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/dmd.110.036715","article-title":"Metabolism and excretion of asenapine in healthy male subjects","volume":"39","author":"van de Wetering-Krebbers","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2020.115239_bb0095","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1734-1140(12)70938-6","article-title":"Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver","volume":"64","author":"W\u00f3jcikowski","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.taap.2020.115239_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s43440-020-00089-z","article-title":"In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions","author":"W\u00f3jcikowski","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.taap.2020.115239_bb0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20303653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20303653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:52:12Z","timestamp":1758574332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X20303653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":21,"alternative-id":["S0041008X20303653"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2020.115239","relation":{},"ISSN":["0041-008X"],"issn-type":[{"type":"print","value":"0041-008X"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2020.115239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115239"}}